EP1824474A1 - Composition anthelminthique - Google Patents
Composition anthelminthiqueInfo
- Publication number
- EP1824474A1 EP1824474A1 EP05823841A EP05823841A EP1824474A1 EP 1824474 A1 EP1824474 A1 EP 1824474A1 EP 05823841 A EP05823841 A EP 05823841A EP 05823841 A EP05823841 A EP 05823841A EP 1824474 A1 EP1824474 A1 EP 1824474A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- anthelmintic
- praziquantel
- anthelmintic composition
- oxyclosanide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
Definitions
- This invention relates to an anthelmintic composition.
- Praziquantel and Oxyclosanide are known anthelmintics and, for this purpose, are generally available in suspensions. Although fairly effective, the suspensions do suffer the disadvantage that they are difficult to formulate and are relatively limited as to the amount of immediately bioavailable active compound that they contain.
- an anthelmintic composition comprising an active ingredient selected from any one or more of Praziquantel, Closantel Sodium, Levimasole and Oxyclosanide dissolved in propylene glycol.
- compositions to contain between 0.5 and 4%m/v Praziquantel, preferably 2.8%m/v Praziquantel; alternatively for the composition to contain between 1 and 5%m/v Levimasole, preferably 2.5 to 3.75%m/v Levimasole; further alternatively for the composition to contain between 1 and 5%m/v Oxyclosanide, preferably 2.55% Oxyclosanide; still further alternatively for the composition to contain between 1 and 4%m/v Closantel Sodium, preferably 2.5% Closantel Sodium.
- compositions according to the present invention may contain Chlorbutanol and/or benzyl alcohol.
- Preferred concentrations of Chlorbutanol are 2 to 5%m/v, in particular 3,3 to 4,l%m/v; preferred concentrations of benzyl alcohol are 1 to 4%m/v, in particular 2,3 to 2,8%m/v.
- a suitable amount of an active ingredient selected from Praziquantel, Levimasole and Oxyclosanide was dissolved in propylene glycol to provide the solutions of varying concentration. These solutions were tested against suspensions that are available on the market to find concentrations in solution have the same efficacy as suspensions. The results are shown in table below.
- Solution 2 uses has a higher concentration of Praziquantel than the Endotape Suspension. This concentration was selected simply to match that of Solution 1 but it has nonetheless been found that Solution 2 is effective against a much broader spectrum of tape worms than the Endotape Suspension.
- Chlorbutanol and benzyl alcohol are defined as preservatives, in this formulation they function as free radical scavengers, possibly due to their OH groups. According to this theory, degradation releases free radicals, and these free radicals function as a catalyst for further degradation. Hence the preservatives, by functioning as free radical scavengers, retard the degradation process.
- solutions of the invention are easy to formulate, contain less excipients and are more effective than prior art suspensions and highly effective. It will be appreciated, however, that many other embodiments of anthelmintic solutions exists which fall within the scope of the invention, particularly as regards the concentration of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La présente invention concerne une composition anthelminthique qui renferme un ingrédient actif sélectionné parmi le Praziquantel, le Sodium de Closatel, le Lévimasole et l'Oxyclosanide dissous dans du propylène glycol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200410001 | 2004-12-10 | ||
PCT/EP2005/013139 WO2006061214A1 (fr) | 2004-12-10 | 2005-12-08 | Composition anthelminthique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1824474A1 true EP1824474A1 (fr) | 2007-08-29 |
Family
ID=36267185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05823841A Withdrawn EP1824474A1 (fr) | 2004-12-10 | 2005-12-08 | Composition anthelminthique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1824474A1 (fr) |
WO (1) | WO2006061214A1 (fr) |
ZA (1) | ZA200704633B (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563554B2 (en) | 2009-03-17 | 2013-10-22 | Concert Pharmaceuticals, Inc. | Deuterated pyrazinoisoquinoline compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ247278A (en) * | 1991-02-12 | 1995-03-28 | Ancare Distributors | Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier |
NZ248486A (en) * | 1993-08-24 | 1996-07-26 | Ashmont Holdings Limited Subst | Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent |
AU711820B3 (en) * | 1996-07-30 | 1999-10-21 | Ashmont Holdings Limited | Anthelmintic formulations |
US6429211B1 (en) * | 2000-05-23 | 2002-08-06 | Bayer Corporation | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora |
AUPR510001A0 (en) * | 2001-05-18 | 2001-06-14 | Jupitar Pty Ltd | Formulation and method |
GB2386066A (en) * | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
US6991801B2 (en) * | 2003-04-04 | 2006-01-31 | Merial Limited | Topical anthelmintic veterinary formulations |
US7666444B2 (en) * | 2004-02-02 | 2010-02-23 | Wyeth | Antiparasitic composition |
-
2005
- 2005-12-08 EP EP05823841A patent/EP1824474A1/fr not_active Withdrawn
- 2005-12-08 WO PCT/EP2005/013139 patent/WO2006061214A1/fr active Application Filing
-
2007
- 2007-06-07 ZA ZA200704633A patent/ZA200704633B/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2006061214A1 * |
Also Published As
Publication number | Publication date |
---|---|
ZA200704633B (en) | 2008-09-25 |
WO2006061214A1 (fr) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2224651T3 (es) | Metodo para estabilizar composiciones farmaceuticas por medio del uso especial de un antioxidante. | |
EP3042646B1 (fr) | Compositions pharmaceutiques à biodisponibilité souhaitable | |
US20090176887A1 (en) | Biocidal Compositions and Methods | |
EP3895694A1 (fr) | Formulations de bendamustine | |
DK163637B (da) | Fremgangsmaade til fremstilling af et stabilt, vandigt praeparat indeholdende ivermectin | |
CA2476520A1 (fr) | Composition anti-parasitaire longue duree contenant un compose salicylanilide, une espece polymerique et au moins un autre compose anti-parasite | |
NZ599669A (en) | Compositions containing alpha-2-adrenergic agonist components | |
RU2745317C2 (ru) | Фармацевтическая композиция, включающая дорзоламид и бримонидин | |
CA2377024A1 (fr) | Composition ophthalmique | |
EP1121120A1 (fr) | Utilisation d'une composition ophtalmique comprenant de la vitamine a et de la vitamine e | |
CA2405378C (fr) | Solutions stables d'electrolyte de taurolidine | |
US9901576B2 (en) | Stable formulation of phenobarbital sodium injection | |
EP1824474A1 (fr) | Composition anthelminthique | |
CA2230805A1 (fr) | Preservatif pour emulsion; emulsion qui en renferme | |
JP2001261552A (ja) | 点眼液用保存剤 | |
JPS5989617A (ja) | 点眼液 | |
US20090211487A1 (en) | Wood Preservative Composition | |
JP4132807B2 (ja) | ヨウ素系濃縮防殺菌剤組成物 | |
JP4892291B2 (ja) | 眼科用防腐組成物 | |
JP2005270214A (ja) | ホルムアルデヒド放散阻止・消臭・抗菌組成物 | |
JP2005036000A (ja) | 容器への吸着を防止した外用抗真菌組成物 | |
JP2004331606A (ja) | ヨウ素安定化担体、非水溶性固体防殺菌剤組成物及び非水溶性固体防殺菌剤組成物の製造方法 | |
WO2006087528A2 (fr) | Composition biocide | |
JP2023093952A (ja) | 水性組成物 | |
WO2022097654A1 (fr) | Gouttes oculaires contenant du tafluprost |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070710 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20071017 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER ANIMAL HEALTH GMBH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081111 |